Similar articles

• Leuprolide: a review of its effects in animals and man.

  Drago JR, Rohner T, Santen R, Manni A, Lipton A, Harvey H, English H. Drago JR, et al. Br J Clin Pract Suppl. 1985 Mar;37:4-7, 16-9. Br J Clin Pract Suppl. 1985. PMID: 3931664 Review. English, French. No abstract available.
• Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.

  Santen RJ, Warner B. Santen RJ, et al. Urology. 1985 Feb;25(2 Suppl):53-7. Urology. 1985. PMID: 3918377
• [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].

  Fuse H, Akimoto S, Akakura K, Shimazaki J, Murakami S. Fuse H, et al. Hinyokika Kiyo. 1988 Mar;34(3):555-60. Hinyokika Kiyo. 1988. PMID: 3133936 Japanese.
• Phase III studies in prostatic cancer with leuprolide acetate.

  Seely JH. Seely JH. J Androl. 1987 Jan-Feb;8(1):S23-6. J Androl. 1987. PMID: 3104263 Clinical Trial. No abstract available.
• [Studies on hormone-polymer composites in urological field--their application in prostatic cancer therapy].

  Yamanaka H. Yamanaka H. Hinyokika Kiyo. 1983 Dec;29(12):1579-86. Hinyokika Kiyo. 1983. PMID: 6375311 Review. Japanese.